After The Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that Mounjaro has been approved for weight loss in the UK, Second Nature is excited to announce Second Nature'll launch a Mounjaro weight-loss programme!

Pictured: Eli Lilly/iStock, Michael ViEli Lilly bumped up its full-year forecast after the company exceeded revenue expectations in the second quarter. Profit jumped 85% from the same period a year ago, with shares up 9% in premarket trading Tuesday morning on the news.  Total revenue for the quarter was over $8.3 billion for the pharma, a 28% increase over the same quarter last year, beating estimates of $7.58 billion. Growth was driven by its newest blockbuster Mounjaro, breast cancer treatment Verzenio and expanded indications for Jardiance. Lilly’s Type 2 diabetes treatment Mounjaro (tirzepatide), approved in May 2022, led the way in new product growth. The GLP-1 injectable has already jumped to $1.5 billion in sales for the first half of 2023. Currently approved for Type 2 diabetes, Mounjaro is poised to add the hot indication of chronic weight management to its label by the end of this year. However, Lilly said it “has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand.”  Data suggests the drug may be more effective for weight loss than Novo Nordisk’s Wegovy (semaglutide)